Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 14  •  04:00PM ET
4.08
Dollar change
-0.10
Percentage change
-2.39
%
Index- P/E- EPS (ttm)-0.71 Insider Own35.78% Shs Outstand65.02M Perf Week11.17%
Market Cap265.30M Forward P/E- EPS next Y-0.81 Insider Trans0.00% Shs Float41.66M Perf Month18.95%
Enterprise Value136.48M PEG- EPS next Q-0.20 Inst Own45.91% Short Float6.53% Perf Quarter134.48%
Income-62.52M P/S- EPS this Y-31.25% Inst Trans-3.75% Short Ratio1.67 Perf Half Y267.57%
Sales0.00M P/B2.45 EPS next Y-3.17% ROA-37.55% Short Interest2.72M Perf YTD63.20%
Book/sh1.66 P/C1.91 EPS next 5Y-8.67% ROE-47.86% 52W High4.68 -12.82% Perf Year-9.93%
Cash/sh2.14 P/FCF- EPS past 3/5Y- - ROIC-57.76% 52W Low0.97 320.62% Perf 3Y-58.99%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility10.85% 8.31% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-19.69% Oper. Margin- ATR (14)0.34 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.58 Sales Y/Y TTM- Profit Margin- RSI (14)56.40 Recom1.25
Dividend Gr. 3/5Y- - Current Ratio5.58 EPS Q/Q19.34% SMA208.29% Beta0.22 Target Price14.00
Payout- Debt/Eq0.00 Sales Q/Q- SMA5023.66% Rel Volume0.25 Prev Close4.18
Employees30 LT Debt/Eq0.00 EarningsNov 13 BMO SMA200118.90% Avg Volume1.62M Price4.08
IPOSep 03, 2021 Option/ShortYes / Yes EPS/Sales Surpr.-9.78% - Trades Volume398,280 Change-2.39%
Date Action Analyst Rating Change Price Target Change
Nov-04-24Initiated Leerink Partners Outperform $15
Sep-05-24Initiated H.C. Wainwright Neutral $5
May-03-24Initiated Piper Sandler Overweight $26
Oct-10-23Initiated Ladenburg Thalmann Buy $10
Aug-25-23Initiated Oppenheimer Outperform $17
Jun-22-23Initiated Guggenheim Buy $20
Jun-14-23Initiated Chardan Capital Markets Buy $14
May-24-23Initiated Raymond James Strong Buy $20
Nov-13-25 06:30AM
Aug-20-25 06:30AM
Aug-14-25 08:15AM
Jul-17-25 04:30PM
Jul-01-25 06:30AM
06:30AM Loading…
May-27-25 06:30AM
May-20-25 06:30AM
May-08-25 06:30AM
Mar-25-25 06:30AM
Feb-24-25 06:30AM
Dec-23-24 06:30AM
Nov-25-24 06:30AM
Nov-14-24 04:30PM
Nov-07-24 06:30AM
Oct-30-24 06:30AM
06:00AM Loading…
Sep-03-24 06:00AM
Aug-13-24 09:21AM
Aug-12-24 04:05PM
Aug-09-24 04:05PM
Aug-01-24 08:00AM
Jul-12-24 06:10AM
06:08AM
Jun-14-24 06:00AM
Jun-06-24 06:00AM
Jun-03-24 06:00AM
May-31-24 09:55AM
May-29-24 06:00AM
May-24-24 06:18AM
May-15-24 09:55AM
May-14-24 12:00PM
03:26PM Loading…
May-12-24 03:26PM
May-10-24 03:14PM
May-09-24 01:56PM
06:00AM
Apr-25-24 02:18AM
Apr-18-24 09:22AM
Apr-08-24 06:00AM
Mar-28-24 11:54AM
06:00AM
Mar-04-24 06:00AM
Feb-02-24 06:00AM
Jan-08-24 06:00AM
Jan-03-24 06:00AM
Dec-04-23 06:00AM
Nov-14-23 06:00AM
Nov-13-23 06:30AM
Sep-12-23 05:00AM
Sep-05-23 08:55PM
Aug-25-23 09:42AM
Aug-14-23 07:00AM
Jun-23-23 06:30AM
Jun-06-23 06:34AM
04:00AM
Jun-01-23 10:20AM
Apr-27-23 07:39AM
Apr-14-23 05:00AM
Mar-27-23 09:35AM
Mar-21-23 06:13AM
Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thiara ParvinderDirectorNov 25 '24Sale2.731,001,6332,734,4580Nov 27 04:15 PM